CARLSMED, INC.

Carlsmed, Inc. reported a significant increase in revenue for the second quarter and first half of 2026, driven by the commercial launch of its aprevo Technology Platform. Q2 2026 revenue jumped 56.7% to $18.9 million, while year-to-date revenue rose 57.4% to $35.1 million. However, the company's net loss also widened, reaching $10.5 million for Q2 and $19.2 million year-to-date, reflecting increased operating expenses. The company expects to commercially launch its corra Cervical Plating System by December 2026.

Carlsmed reported strong second quarter 2026 financial results, with revenue reaching $18.9 million, marking a 57% year-over-year increase. The company raised its full-year 2026 revenue guidance to a range of $74 million to $78 million, driven by growing momentum in aprevo® procedures and significant surgeon adoption. Despite the revenue growth and expanded gross margins, the net loss for the quarter increased to ($10.5) million, and adjusted EBITDA was ($8.6) million.

Carlsmed, Inc. announced that the Centers for Medicare & Medicaid Services (CMS) has finalized a favorable reimbursement policy for its aprevo® Lumbar spinal fusion procedures. Effective October 1, 2026, these procedures will be assigned to three newly created MS-DRGs (523, 524, and 525), ensuring eligibility for reimbursement. The company anticipates this decision will significantly expand hospital, surgeon, and patient access to the aprevo® procedure, accelerating its adoption and contributing to improved patient outcomes and reduced healthcare costs.

Carlsmed, Inc. announced that its management will participate in two upcoming investor conferences in August 2026. The company will host one-on-one meetings at the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on August 10. Additionally, management will conduct a fireside chat at the Bank of America SMID Cap Virtual Conference on August 12, with a live webcast available for registered participants and archived on the company's investor website.

Carlsmed, Inc. announced it will report its second quarter 2026 financial results after market close on Wednesday, August 5, 2026. Following the release, management will host a conference call and concurrent webcast at 1:30 PM Pacific Time to discuss the results. A live webcast will be accessible via the company's investor relations website, with a replay available afterward.

Carlsmed, Inc. reported a significant increase in revenue for the first quarter of 2026, reaching $16.1 million, a 58% rise year-over-year. Despite this growth, the company's net loss widened to $8.7 million. The quarter also saw the exercise of outstanding warrants and continued progress in its cervical spine fusion product line, including the first personalized corra cervical plating procedure. The company believes its existing cash on hand will be sufficient for at least the next 12 months.

Carlsmed, Inc. reported strong first-quarter 2026 financial results, with revenue growing 58.2% year-over-year to $16.1 million. The company also raised its full-year 2026 revenue guidance to a range of $72 million to $77 million. Despite an increased net loss of ($8.7) million, Carlsmed highlighted significant business achievements, including positive clinical data for its aprevo® implants and the debut of its corra™ personalized cervical plating system.

Carlsmed, Inc. announced that Chairman and CEO Mike Cordonnier will participate in four investor conferences in May and June 2026. He is scheduled for fireside chats and one-on-one meetings at the Bank of America, Goldman Sachs, and Truist Securities conferences, and will host one-on-one meetings at the Jefferies conference. Live webcasts will be available for registered participants for the fireside chat presentations.

Carlsmed, Inc. announced it will release its first quarter 2026 financial results after market close on Tuesday, May 5, 2026. Following the release, the company's management will host a conference call and concurrent webcast at 1:30 PM Pacific Time to discuss the results. A replay of the webcast will be made available on Carlsmed's website shortly after the call concludes.